CLINICAL UTILITY OF INTERLEUKIN-1 INHIBITORS IN PEDIATRIC SEPSIS.
| Autor: | Manchikalapati R, Schening J; Division of Pulmonology, Section of Allergy-Immunology, Phoenix Children's Hospital, Phoenix, Arizona., Farias AJ; Division of Critical Care, Phoenix Children's Hospital, Phoenix, Arizona., Sacco KA |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Shock (Augusta, Ga.) [Shock] 2024 Mar 01; Vol. 61 (3), pp. 340-345. Date of Electronic Publication: 2023 Sep 05. |
| DOI: | 10.1097/SHK.0000000000002223 |
| Abstrakt: | Abstract: The pathophysiology of pediatric sepsis is characterized by increased innate immune activation earlier in life. Interleukin-1 is a proinflammatory cytokine implicated in the pathophysiology of sepsis, and ferritin is a stable surrogate biomarker for elevated IL-1 levels. Data in adult sepsis have shown that use of anakinra, an anti-IL-1 receptor antagonist, led to improved clinical outcomes in patients with features of macrophage activation and hyperferritinemia. However, data in pediatric sepsis are lacking. Our narrative review sought to highlight the current understanding of using IL-1 inhibitors in pediatric sepsis. We identified five studies including one case report and four retrospective case series that described clinical outcomes in relation to use of anakinra for secondary hemophagocytic lymphohistiocytosis (HLH). A few patients in this pooled heterogenous cohort of 72 patients had concomitant infection meeting the criteria for sepsis. All studies measured ferritin levels and reported a decrease in ferritin after initiating anakinra. Twelve patients died after treatment initiation. There was no clear comparison in clinical outcomes between infected and noninfected patients. The pathophysiology of pediatric sepsis suggests that there is a need for blinded clinical trials using targeted immunomodulation such as IL-1 inhibitors in pediatric sepsis cohort with an immunophenotype suggesting increased innate immune activation. Competing Interests: Conflict of Interest: K.S. is a consultant and speaker for Horizon Therapeutics, Pharming N.V., and consultant for Enzyvant Therapeutics. (Copyright © 2023 by the Shock Society.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|